Second-line ramucirumab therapy for advanced hepatocellular carcinoma (REACH): an East Asian and non-East Asian subgroup analysis — Joon Oh Park (2016) | RDL Network
Second-line ramucirumab therapy for advanced hepatocellular carcinoma (REACH): an East Asian and non-East Asian subgroup analysis
Article 2016 en
Authors
JP
Joon Oh Park
BR
Baek‐Yeol Ryoo
CY
Chia-Jui Yen
Abstract
1 min read
In East Asians and non-East Asians, ramucirumab did not significantly prolong overall survival. In patients with baseline alpha-fetoprotein ≥ 400 ng/mL, a potentially larger survival benefit was observed in both subgroups. Safety for East Asians was similar to non-East Asians.
Masatoshi Kudo, Peter R. Galle, Josep M. Llovet, Richard S. Finn, Arndt Vogel, Kenta Motomura, Éric Assenat, Philippe Merle, Giovanni Brandi, Bruno Daniele, Takuji Okusaka, Jiří Tomášek, Christophe Borg, Vincenzo Dadduzio, Manabu Morimoto, Marc Pracht, Min‐Hua Jen, N. Drove Ubreva, Ryan C. Widau, Kenta Shinozaki, Reigetsu Yoshikawa, Andrew X. Zhu
Peter R. Galle, Masatoshi Kudo, Josep M. Llovet, Richard S. Finn, Mark Karwal, Denis Pezet, Tae‐You Kim, Tsai‐Sheng Yang, Sara Lonardi, Jiří Tomášek, Jean-Marc Phélip, Yann Touchefeu, Su‐Jin Koh, Guido Stirnimann, Kun Liang, Kenyon D. Ogburn, Chunxiao Wang, Paolo Abada, Ryan C. Widau, Andrew X. Zhu
Andrew X. Zhu, Richard S. Finn, Yoon‐Koo Kang, Chia-Jui Yen, Peter R. Galle, Josep M. Llovet, Éric Assenat, Giovanni Brandi, Kenta Motomura, Izumi Ohno, Bruno Daniele, Arndt Vogel, Tatsuya Yamashita, Chih‐Hung Hsu, Guido Gerken, John Bilbruck, Yanzhi Hsu, Kun Liang, Ryan C. Widau, Chunxiao Wang, Paolo Abada, Masatoshi Kudo
Josep M. Llovet, Amit G. Singal, Augusto Villanueva, Richard S. Finn, Masatoshi Kudo, Peter R. Galle, Masafumi Ikeda, Sophie Callies, Louise M. McGrath, Chunxiao Wang, Paolo Abada, Ryan C. Widau, Elena Gonzalez-Gugel, Andrew X. Zhu
Discussion(0)
No comments yet. Be the first to comment.